Rebate Reshuffle: Could Pharma Foot The Bill To Offset Higher Premiums?
Bernstein Research analysts said CMS could charge pharmaceutical manufactures a fee to offset increases in insurance premiums anticipated from the elimination of rebates in a "win-win" move.
You may also be interested in...
Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.
But CMS also advises Medicare Part D plans to develop bids for the 2020 plan year that include rebates, since the final version of the HHS rule eliminating the anti-kickback safe harbor for rebates may not be released in time for the June 3 bid submission deadline.
Faced with a proposed regulation that aims to eliminate rebates and an upcoming hearing on Capitol Hill, US pharmacy benefit managers including OptumRx are working to validate the concept of rebates when redirected to patients at the point-of-sale.